These insights, coupled with new tools for targeting transcription factors and chromatin-modifying proteins (Table 1), suggest that small-molecule modulators of transcription will be useful for therapeutic manipulation of cytokine networks. RORγt (retinoid-related orphan receptor γt) is a nuclear hormone receptor (NHR) implicated in CD by human genetics that promotes differentiation of TH17 cells (Figure 1d) [23• and 40]. Although a monoclonal antibody targeting IL-17A (secukinumab) has demonstrated potential for treating psoriasis and ankylosing spondylitis, it is ineffective in CD patients [41]. The failure of IL-17A blockade in CD may suggest the need to suppress a

wider set of cytokines produced by TH17 cells, possibly by interfering with TH17 differentiation. RORγt contains a deep binding pocket for endogenous small-molecule ligands, which has facilitated development of RORγt BLZ945 antagonists that suppress TH17 cell differentiation and display efficacy in murine models of graft-versus-host disease, demyelinating neurological disorders and cutaneous inflammation [42 and 43•]. Their established roles in immune cell Galunisertib purchase function, coupled with

their ability to bind small molecules, make other NHRs intriguing drug targets. Activation of the retinoic acid receptor (RAR) by vitamin A metabolites enhances development of anti-inflammatory CD4+ regulatory T cells (Tregs), an effect that contributes to the therapeutic activity of all-trans retinoic acid in murine models of autoimmune disease [44]. Binding of the aryl hydrocarbon receptor (AhR) by the tryptophan metabolite kynurenine stimulates IL-10 production by DCs and promotes Treg differentiation [45 and 46]; two mechanisms that may underlie the finding that sub-lethal doses of bacteria enhance resistance to subsequent infections [47]. NHRs often work in concert with chromatin-modifying enzymes,

several classes of which have been targeted with small molecules to modulate cytokine production. The novel small-molecule inhibitor of the Jumonji family histone demethylases JMJD3 and UTX (GSK-J4) suppresses inflammatory cytokine production in macrophages [48••]. Histone deacetylase (HDAC) inhibitors targeting multiple isoforms suppress inflammatory cytokine production by macrophages, promote Treg selleck differentiation and display efficacy in murine models of inflammation [49]. Of note, physiological concentrations of the microbial metabolite and pan-HDAC inhibitor butyrate specifically suppress IL-6, IL-12 and nitric oxide production in gut macrophages suggesting that HDAC inhibition may serve to limit autoinflammatory responses to commensal microbes [13]. While Hdac3−/− murine macrophages display reduced inflammatory cytokine production [ 50], selective deletion of HDAC3 in intestinal epithelial cells alters intestinal architecture and increases sensitivity to experimentally induced colitis [ 51].